New York | May 02, 2018 – HC2 Holdings, Inc. (“HC2”) (NYSE:HCHC), a diversified holding company, announced today that BeneVir Biopharm, Inc. (“BeneVir”), a privately-held biotechnology company developing oncolytic immunotherapies for the treatment of cancer, has entered into a definitive agreement to be acquired by Janssen Biotech, Inc. (“Janssen”).
BeneVir is a portfolio company within HC2’s Pansend Life Sciences (“Pansend”) subsidiary. Pansend is led by David A. Present M.D., Founder and General Partner, and Cherine Eldumiati Plumaker, Founder and General Partner. HC2 made its initial investment in BeneVir in 2014, and currently owns approximately 76 percent of the company’s equity.
